SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Based Chad

Based Chad is trending as community members highlight its relative strength compared to other memecoins amid market dips, emphasizing its diamond-handed community and unique buyback mechanisms. Discussions also suggest a potential connection to Coinbase, with executives reportedly holding the token and the meme gaining traction on the platform. The community anticipates further growth, pointing to upcoming video game integrations and staking opportunities.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

WBD is trending amid speculation around potential bids from Comcast, Netflix and Paramount, with some community members discussing the likelihood of a deal being reached by the end of the year. Community members are debating the potential bid prices and who might win the bidding war, with many speculating on potential offers from other major players. Some traders are taking bullish positions, while others express skepticism about management and debt.

Columbus Circle Capital Corp. I operates as a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which refer to throughout this prospectus as initial business combination. The company was founded in June 2024 and is headquartered in New York, NY.

Columbus Circle Capital Corp I - Ordinary Shares - Class A

BRR is trending as chatter swirls around its upcoming merger vote and potential exposure to Bitcoin, with some highlighting the involvement of Eric Jackson and Anthony Pompliano. The community is speculating on a potential short squeeze and the impact of amendments to the deal, with excitement building for a possible rally.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is trending as the community discusses unusual options activity and potential catalysts, including a possible lidar deal. The stock's momentum and recent 52-week highs are balanced against concerns about potential pullbacks and changing EV strategies. Traders are also monitoring the broader automotive sector and macroeconomic factors influencing GM's performance.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad (MON) is trending as the community discusses its potential as a high-speed, EVM-compatible blockchain, with some comparing it to early Ethereum and Solana. The community is focused on its Coinbase listing and potential for staking rewards, while also debating its market cap and long-term viability. Discussions also include speculation around future exchange listings and potential partnerships.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSM is trending as community members highlight its strong financials and pipeline, especially Auvelity's potential in treating Alzheimer's agitation. Recent analyst upgrades and positive trial data are fueling optimism, though some caution against over-reliance on pipeline developments. Discussions also include potential buyout scenarios and the impact of regulatory decisions on the stock's future.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano is trending amid mixed community sentiment, with some expressing frustration over its price performance compared to Bitcoin and other altcoins.  Discussions also involve comparisons to Keeta, highlighting Cardano's methodical approach versus Keeta's focus on high-speed, compliant infrastructure; the potential launch of Midnight token, and speculation around an ADA ETF.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visa is trending due to its partnership with Aquanow to expand stablecoin (USDC) payments in Central and Eastern Europe, the Middle East, and Africa, which the community sees as a move to strengthen its blockchain-based cross-border capabilities.  Community members are also discussing option activity and technical analysis, while others debate whether it is overvalued compared to Mastercard. Some traders are also watching for a potential breakout with various price targets being mentioned.

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ. The IXIARO is an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis in adults, adolescents, children, and infants aged two months and older. The DUKORAL is a drinkable vaccine that helps prevent diarrhea caused by heat-labile toxin-producing ETEC, as well as cholera. The IXCHIQ is a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also offers additional vaccines, including VLA1553, VLA15, VLA160, VLA200, VLA1601 and others. Valneva was founded on May 28, 2013 and is headquartered in Saint-Herblain, France.

Valneva SE - ADR

Valneva is trending due to positive Phase 2 booster results for its Lyme disease vaccine, developed in partnership with Pfizer, fueling speculation about a potential buyout. The community is focused on the significant revenue potential of the Lyme vaccine and anticipating Phase 3 trial data. Some investors express caution, referencing past setbacks, while others see the current low trading volume as an opportunity for exponential gains upon positive news.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices approach all-time highs, fueled by speculation around potential Fed rate cuts and renewed interest in precious metals as a hedge against economic uncertainty. Community members are discussing technical breakouts, potential for a silver squeeze, and historical inflation-adjusted valuations, while some express concerns about market manipulation and potential pullbacks. The broader context involves increased industrial demand for silver and its role as a safe-haven asset amid global economic concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates

Bluebird Bio, Inc. (BLUE) said on Wednesday that global investment firms Carlyle (CG) and SK Capital Partners have agreed to purchase all its outstanding shares and take the company private for $5 per share upfront.Under the terms of the <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.bluebirdbio.com/news-releases/news-release-details/carlyle-sk-capital-partners-and-bluebird-bio-amend-merger">amended</a> agreement, Bluebird stockholders can elect to receive either $3 per share in cash plus a contingent value right (CVR) of $6.84 per share in cash payable upon achievement of a net sales milestone or $5 per share in cash.The upfront payment of $5 represents a 51% premium to Bluebird’s closing price of $3.31 on Tuesday.Shares of the company traded over 50% higher on Wednesday morning.Gene therapy maker Bluebird first entered a definitive agreement with Carlyle and SK Capital in February. As per the original agreement, stockholders had only one option of receiving $3.00 per share in cash plus a CVR of $6.84 per share.Bluebird said the amended agreement allows an alternative for stockholders who would prefer greater upfront cash consideration instead of the potential upside of the CVR.The Bluebird board of directors recommended that shareholders tender their shares in support of the transaction by 11:59 p.m., New York City time, on May 29, 2025, following which the tender offer would expire.The company said that unless a majority of stockholders tender their shares, Bluebird is at significant risk of defaulting on its loan agreements with Hercules Capital, and it is extremely unlikely that stockholders would receive any consideration for their shares in a bankruptcy or liquidation.On Stocktwits, retail sentiment around Bluebird rose within the ‘bullish’ territory while message volume jumped from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:633/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_14_at_10_22_02_AM_png_1451c7b7eb.webp" alt="BLUE's Sentiment Meter and Message Volume as of 10:20 a.m. ET on May 14, 2025 | Source: Stocktwits" width="633" height="60"><figcaption>BLUE's Sentiment Meter and Message Volume as of 10:20 a.m. ET on May 14, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/BLUE">BLUE stock</a> is down by about 43% this year and about 77% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dynatrace-technology-q4-2025-earnings/chiqru4RbNS">Dynatrace Stock Rises On Upbeat Q4 Earnings, Retail Turns Extremely Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Bluebird bio logo is seen on a smartphone and a pc screen in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Bluebird Bio Stock Soars On Higher Upfront Payment Under Amended Merger Deal: Retail Gets More Bullish 

The upfront payment of $5 represents a 51% premium to Bluebird’s closing price of $3.31 on Tuesday.

Equity

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, AVTE, BLUE on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, AVTE, BLUE on Behalf of Shareholders SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, AVTE, BLUE on Behalf of Shareholders...

BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of bluebird bio, Inc. (NasdaqGS: BLUE) to Carlyle...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc. ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc. PR Newswire NEW YORK, Feb. 21...

Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday...

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of bluebird bio, Inc. - BLUE

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of bluebird bio, Inc. - BLUE $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of bluebird bio, Inc. - BLUE PR...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BLUE, VOXX, CARA, CYTH on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BLUE, VOXX, CARA, CYTH on Behalf of Shareholders SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BLUE, VOXX, CARA, CYTH on Behalf of...

Shareholder Alert: Ademi LLP investigates whether bluebird bio, Inc. is obtaining a Fair Price for its Public Shareholders

Ademi LLP is investigating bluebird (Nasdaq: BLUE) for possible breaches of fiduciary duty and other violations of law in its transaction with Carlyle and SK Capital. Click here to learn how to join...

BLUE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of bluebird bio, Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of bluebird bio, Inc. (NASDAQ: BLUE) to Carlyle Group and SK Capital Partners, LP is fair to bluebird shareholders...

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Bluebird bio Inc

$AMZN

$MSFT

$GOOGL

$ORCL

Which cloud infrastructure stock offers the best long-term opportunity right now?

Current Price	$4.97
Prev Close	$4.97
Open	$4.74
Dividend Yield	0.00%
50-Day Moving Average	$4.56
Beta	1.63
Avg. Volume	1.01M
PE Ratio	-0.24

52-Week High	$28.60
52-Week Low	$3.20
Market Capitalization	$48.67M
EPS (Annual)	-$24.84
Price to Book	-0.84
Revenue Per Employee	$337,931.45
Enterprise Value/EBITDA	N/A

BLUE
Bluebird bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BLUE News

BLUEBluebird bio Inc